Skip to main content

Articles

Page 25 of 335

  1. Ovarian cancer (OC) is a highly lethal gynecological malignancy. Extensive research has shown that OC cells undergo significant metabolic alterations during tumorigenesis. In this study, we aim to leverage the...

    Authors: Linfeng Chen, Qiming Tang, Keying Zhang, Qianyang Huang, Yun Ding, Bo Jin, Szumam Liu, KuoYuan Hwa, C. James Chou, Yani Zhang, Sheeno Thyparambil, Weili Liao, Zhi Han, Richard Mortensen, James Schilling, Zhen Li…
    Citation: BMC Cancer 2023 23:844
    Content type: Research article Published on:

  2. Non-coding microRNAs (miRNAs) play critical roles in tumor progression and hold great promise as therapeutic agents for multiple cancers. MicroRNA 29a (miR-29a) is a tumor suppressor miRNA that inhibits cancer...

    Authors: Seung-Myoung Son, Jieun Yun, Dong-Wook Kim, Young-Suk Jung, Sang-Bae Han, Yong Hee Lee, Hye Sook Han, Chang Gok Woo, Ho-Chang Lee and Ok-Jun Lee
    Citation: BMC Cancer 2023 23:843
    Content type: Research Published on:

  3. The carcinogenesis of hepatocellular carcinoma is complicated, and genetic factor may have the role in the malignant transformation of liver cells. IL-10 gene polymorphisms have been investigated for their pot...

    Authors: Teresa Tan Yen Mei, Htar Htar Aung, Wong Siew Tung and Cho Naing
    Citation: BMC Cancer 2023 23:842
    Content type: Research Published on:

  4. Breast cancers with 1–10% cell staining for estrogen receptor (ER) present particular clinical features. The clinical data of estrogen receptor expression level and treatment effect are limited, particularly r...

    Authors: Hai-long Chen, Feng-bo Huang, Qiang Chen and Yong-chuan Deng
    Citation: BMC Cancer 2023 23:841
    Content type: Research Published on:

  5. Head neck squamous cell carcinoma (HNSCC) is one of the most common malignant tumors which ranks the sixth incidence in the world. Although treatments for HNSCC have improved significantly in recent years, its...

    Authors: Ce Li, Rui Guan, Wenming Li, Dongmin Wei, Shengda Cao, Fen Chang, Qun Wei, Ran Wei, Long Chen, Chenyang Xu, Kainan Wu and Dapeng Lei
    Citation: BMC Cancer 2023 23:840
    Content type: Research Published on:

  6. Colorectal cancer survival has improved in recent decades but there are concerns that survivors may develop kidney problems due to adverse effects of cancer treatment or complications of the cancer itself. We ...

    Authors: Kirsty Andresen, Helena Carreira, Helen Strongman, Helen I. McDonald, Sara Benitez-Majano, Kathryn E. Mansfield, Dorothea Nitsch, Laurie A. Tomlinson and Krishnan Bhaskaran
    Citation: BMC Cancer 2023 23:839
    Content type: Research article Published on:

  7. Colorectal cancer (CRC) is among the most frequently diagnosed cancers. Approximately 20–30% of stage I-III CRC patients develop a recurrent tumour or metastases after curative surgical resection. Post-operati...

    Authors: Hidde Swartjes, Seyed M. Qaderi, Steven Teerenstra, Jose A. E. Custers, Marloes A. G. Elferink, Bob J. van Wely, Jacobus W. A. Burger, Wilhelmina M. U. van Grevenstein, Peter van Duijvendijk, Emiel G. G. Verdaasdonk, Marnix A. J. de Roos, Veerle M. H. Coupé, Geraldine R. Vink, Cornelis Verhoef and Johannes H. W. de Wilt
    Citation: BMC Cancer 2023 23:838
    Content type: Study Protocol Published on:

  8. RNASET2 has been identified as an oncogene with anti-angiogenic and immunomodulatory effects in a variety of cancers, but its function in clear cell renal cell carcinoma (ccRCC) is still not well understood.

    Authors: Yifu Liu, Zhicheng Zhang, Ping Xi, Ru Chen, Xiaofeng Cheng, Ji Liu, Qiqi Zhu, Yechen Nie, Ting Sun, Binbin Gong and Siyuan Wang
    Citation: BMC Cancer 2023 23:837
    Content type: Research Published on:

  9. Many oncology physicians are confronted with the topic of complementary and integrative medicine (CIM) by cancer patients. This study examined whether a blended learning (e-learning and a workshop) to train on...

    Authors: Stefanie M. Helmer, Alizé A. Rogge, Ryan King, Claudia Canella, Daniel Pach and Claudia M. Witt
    Citation: BMC Cancer 2023 23:836
    Content type: Research Published on:

  10. Loss of expression of the gene ataxia-telangiectasia mutated (ATM), occurring in patients with multiple primary malignancies, including pancreatic cancer, is associated with poor prognosis. In this study, we inve...

    Authors: Jingyu Xun, Hideo Ohtsuka, Katsuya Hirose, Daisuke Douchi, Shun Nakayama, Masaharu Ishida, Takayuki Miura, Kyohei Ariake, Masamichi Mizuma, Kei Nakagawa, Takanori Morikawa, Toru Furukawa and Michiaki Unno
    Citation: BMC Cancer 2023 23:835
    Content type: Research Published on:

  11. Osteoblastic bone reaction (OBR) refers to an increase in bone density at the site of bone metastasis or the appearance of new sclerotic bone lesions after anticancer treatment. OBR can be misunderstood as dis...

    Authors: Kensuke Kanaoka, Hiromitsu Sumikawa, Shunsuke Oyamada, Akihiro Tamiya, Yuji Inagaki, Yoshihiko Taniguchi, Keiko Nakao, Yoshinobu Matsuda and Kyoichi Okishio
    Citation: BMC Cancer 2023 23:834
    Content type: Research Published on:

  14. Heterogeneous tumor cells are thought to be a significant factor in the failure of endocrine therapy in estrogen receptor-positive (ER+) cancers. Culturing patient-derived breast cancer cells (PDBCCs) provides...

    Authors: Seungyeon Ryu, So-Hyun Yoon, Junhyuk Song, Yoonjung Choi, Sangeun Lee, Moonjou Baek, Han-Byoel Lee, Sook Young Jeon, Sangyong Jon, Daeyoup Lee, Hoe Suk Kim and Wonshik Han
    Citation: BMC Cancer 2023 23:831
    Content type: Research Published on:

  15. Persistent high-risk Human papillomavirus (HR-HPV) infections are the main cause of cervical cancer. Cumulative evidence implicates regulatory T cells (Tregs) as a critical factor in the failure to eliminate H...

    Authors: Devamani Chetty-Sebastian and Alain G. Assounga
    Citation: BMC Cancer 2023 23:830
    Content type: Research Published on:

  17. The goal was to investigate the feasibility of the registration generative adversarial network (RegGAN) model in image conversion for performing adaptive radiation therapy on the head and neck and its stabilit...

    Authors: Zhenkai Li, Qingxian Zhang, Haodong Li, Lingke Kong, Huadong Wang, Benzhe Liang, Mingming Chen, Xiaohang Qin, Yong Yin and Zhenjiang Li
    Citation: BMC Cancer 2023 23:828
    Content type: Research Published on:

  20. Effective identification and development of new molecular methods for the diagnosis, treatment and prognosis of lung adenocarcinoma (LUAD) remains an urgent clinical need. DNA methylation patterns at cytosine ...

    Authors: Gui Cheng, Jun Wu, Mei Ji, Wenwei Hu, Changping Wu and Jingting Jiang
    Citation: BMC Cancer 2023 23:825
    Content type: Research Published on:

  21. Wilms’ tumour gene 1 (WT1) is clearly recognized as a tumour promoter in diversiform of human malignancies. Nevertheless, knowledge of its expression, functions and potential molecular mechanisms in non-small ...

    Authors: Xuebing Li, Wenzhe An, Hongli Pan, Yaguang Fan, Hua Huang, Yixuan Wang, Wang Shen, Lingling Zu, Fanrong Meng and Xuexia Zhou
    Citation: BMC Cancer 2023 23:824
    Content type: Research Published on:

    The Correction to this article has been published in BMC Cancer 2023 23:909

  22. The objective of this study is to evaluate the cost-effectiveness of adding pembrolizumab to the standard first-line therapy of advanced biliary tract cancer (BTC) with gemcitabine and cisplatin from the persp...

    Authors: Zhiwei Zheng, Ling Fang and Hongfu Cai
    Citation: BMC Cancer 2023 23:823
    Content type: Research Published on:

  24. Esophageal squamous cell carcinoma (ESCC) is a prevalent malignant tumor worldwide. Circular RNA (circRNA) is of great value in tumorigenesis progression. However, the mechanism of circFNDC3B in ESCC remains t...

    Authors: Dan Song, Ziqi Ye, Fangyu Chen, Liangliang Zhan and Xinchen Sun
    Citation: BMC Cancer 2023 23:821
    Content type: Research Published on:

  25. Global annual cancer incidence is forecast to rise to 27.5 M by 2040, a 62% increase from 2018. For most cancers, prevention and early detection are the most effective ways of reducing mortality. This study ma...

    Authors: Emma L. O’Dowd, Samuel W. D. Merriel, Vinton W. T. Cheng, Sam Khan, Lynne M. Howells, Dipesh P. Gopal, Elizabeth A. Roundhill, Paul M. Brennan, Philip A. J. Crosbie, Richard D. Neal, Karen Brown, Emma J. Crosbie and David R. Baldwin
    Citation: BMC Cancer 2023 23:820
    Content type: Research Published on:

  26. Protein Kinase C-epsilon (PKCε) is a member of the novel subfamily of PKCs (nPKCs) that plays a role in cancer development. Studies have revealed that its elevated expression levels are associated with cervica...

    Authors: Sameen Zafar, Khushbukhat Khan, Yasmin Badshah, Kanza Shahid, Janeen H. Trembley, Amna Hafeez, Naeem Mahmood Ashraf, Hamid Arslan, Maria Shabbir, Tayyaba Afsar, Ali Almajwal and Suhail Razak
    Citation: BMC Cancer 2023 23:819
    Content type: Research Published on:

    The Correction to this article has been published in BMC Cancer 2023 23:963

  27. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and has a poor prognosis. Identifying biomarkers based on molecular mechanisms is critical for early diagnosis, timely treatment, and i...

    Authors: Jungwook Roh, Boseong Kim, Mijung Im, Wonyi Jang, Yeonsoo Chae, JiHoon Kang, BuHyun Youn and Wanyeon Kim
    Citation: BMC Cancer 2023 23:818
    Content type: Research Published on:

  28. Immune checkpoint inhibitors have revolutionized the treatment of patients with advanced urothelial carcinoma (UC) in the frontline and relapsed settings. Lebanon has one of the highest incidence of UC worldwi...

    Authors: Sarah Nasr, Fadi G. Haddad, Joseph Khazen, Joseph Kattan and Viviane Trak-Smayra
    Citation: BMC Cancer 2023 23:817
    Content type: Research Published on:

  29. This network meta-analysis aimed to assess the comparative efficacy and safety of combinations involving three cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapies (ETs) in patients with met...

    Authors: Yiyuan Liu, Jinyao Wu, Zeqi Ji, Lingzhi Chen, Juan Zou, Jiehua Zheng, Weixun Lin, Jiehui Cai, Yaokun Chen, Daitian Zheng, Yexi Chen and Zhiyang Li
    Citation: BMC Cancer 2023 23:816
    Content type: Research Published on:

  31. Patient and Public Involvement (PPI) is slowly but steadily being implemented in all phases of clinical research. As part of the European project “Building Data Rich Clinical Trials” a survey was launched to i...

    Authors: Paola Mosconi, Cinzia Colombo, Pasquale Paletta, Laura Gangeri, Chiara Pellegrini, Elena Garralda, Rosalba Miceli and Cinzia Brunelli
    Citation: BMC Cancer 2023 23:814
    Content type: Research Published on:

  32. Lymphovascular invasion (LVI) indicates resistance to preoperative adjuvant chemotherapy and a poor prognosis and can only be diagnosed by postoperative pathological examinations in breast cancer. Thus, a tech...

    Authors: Yue Li, Xiaomin Wu, Yueqiong Yan and Ping Zhou
    Citation: BMC Cancer 2023 23:813
    Content type: Research Published on:

  33. This study aimed to investigate the association between baseline serum tumor markers (STMs) (carcinoembryonic antigen [CEA], neuron-specific enolase [NSE], cytokeratin-19 fragment [CYFRA21-1], carbohydrate ant...

    Authors: Jian Huang, Yi Xiao, Yubin Zhou, Huiyin Deng, Zihao Yuan, Longyan Dong, Jun Lan, Xiane Li, Gaijiao Liu, Hao Hu, Shaohong Huang and Xiongwen Yang
    Citation: BMC Cancer 2023 23:812
    Content type: Research Published on:

  34. Cancer is one of the main causes of human death. Here, we focus on the B-cell lymphoma 7 protein family member B (BCL7B) gene, an accessory subunit of the SWI/SNF chromatin-remodelling complex. To characterize...

    Authors: Sayaka Higuchi, Yuji Suehiro, Luna Izuhara, Sawako Yoshina, Akira Hirasawa and Shohei Mitani
    Citation: BMC Cancer 2023 23:811
    Content type: Research Published on:

  35. Nivolumab and pembrolizumab have not been directly compared in clinical trials, and the aim of this study is to investigate the efficacy and safety of nivolumab versus pembrolizumab in patients with advanced h...

    Authors: Yen-Hao Chen, Ching-Hua Tsai, Yen-Yang Chen, Chih-Chi Wang, Jing-Houng Wang, Chao-Hung Hung and Yuan-Hung Kuo
    Citation: BMC Cancer 2023 23:810
    Content type: Research Published on:

  36. Lung cancer has been the leading cause of American deaths from cancer. Although Medicare started covering lung cancer screening (LCS) with low-dose computed tomography (LDCT) in 2015, the uptake of LDCT-LCS re...

    Authors: Jiang Li, Cheryl D. Stults, Su-Ying Liang and Meghan Martinez
    Citation: BMC Cancer 2023 23:809
    Content type: Research Published on:

  37. Glioblastoma (GBM) is the most malignant glioma, with poor survival rates and prognosis. Several studies have reported the abnormal expression of circular RNAs (circRNAs) and their functions in the malignant b...

    Authors: Cheng Tan, Jun Wei, Zhaohui Li, Nan Tian, Zhengming Wang, Guan Wang, Liang Han and Yu Tian
    Citation: BMC Cancer 2023 23:808
    Content type: Research Published on:

  38. Breast cancer susceptibility gene (BRCA) mutation carriers are at an increased risk for breast, ovarian, prostate and pancreatic cancers. However, the role of BRCA is unclear in colorectal cancer; the results ...

    Authors: Zhewen Feng, Xiaobao Yang, Mingwei Tian, Na Zeng, Zhigang Bai, Wei Deng, Yanyan Zhao, Jianru Guo, Yingchi Yang, Zhongtao Zhang and Yun Yang
    Citation: BMC Cancer 2023 23:807
    Content type: Research Published on:

  39. HeberFERON is a co-formulation of α2b and γ interferons, based on their synergism, which has shown its clinical superiority over individual interferons in basal cell carcinomas. In glioblastoma (GBM), HeberFER...

    Authors: Jamilet Miranda, Dania Vázquez-Blomquist, Ricardo Bringas, Jorge Fernandez-de-Cossio, Daniel Palenzuela, Lidia I. Novoa and Iraldo Bello-Rivero
    Citation: BMC Cancer 2023 23:806
    Content type: Research Published on:

  40. This study sought to compare the benefits and safety of agents including Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors, and h...

    Authors: Danyang Ji, Yang Luo, Jiayu Wang, Shanshan Chen, Bo Lan, Fei Ma, Binghe Xu and Ying Fan
    Citation: BMC Cancer 2023 23:805
    Content type: Research Published on:

  41. Cuproptosis is a newly discovered programmed cell death dependent on mitochondrial respiratory disorder induced by copper overload. Pyruvate dehydrogenase E1 subunit beta (PDHB) is one of the cuproptosis genes...

    Authors: Hu Wang, Zhan Yang, Xingyu He, Fengran Guo, Hao Sun, Sen Xu, Chao Xu, Zhu Wang, Hongzhuang Wen, Zhihai Teng, Yaxuan Wang and Zhenwei Han
    Citation: BMC Cancer 2023 23:804
    Content type: Research Published on:

  42. Cervical cancer represents one of the most prevalent cancers among women worldwide, particularly in low- and middle-income nations. Oncolytic viruses (OVs) can infect cancer cells selectively and lethally with...

    Authors: Mehdi Samadi, Talat Mokhtari-Azad, Ahmad Nejati, Zahra Norooz-Babaei, Abbas Rahimi Foroushani, Mohammad Reza Haghshenas, Fatemeh Adjaminejad, Hedieh Zargaran, Vahid Salimi and Amir Ghaemi
    Citation: BMC Cancer 2023 23:803
    Content type: Research Published on:

  43. We aimed to identify tumor-associated antigen (TAA) biomarkers through bioinformatic analysis and experimental verification, and to evaluate a panel of autoantibodies against tumor-associated antigens (TAAbs) ...

    Authors: Weihong Xie, Guiying Sun, Junfen Xia, Huili Chen, Chen Wang, Juan Lin and Peng Wang
    Citation: BMC Cancer 2023 23:802
    Content type: Research Published on:

  44. Giant breast malignant phyllodes tumor or sarcoma (GBPS) are rare entities with diameter larger than 10 cm and variously histological pleomorphisms. This disease poses a significant threat to the quality of li...

    Authors: Naiquan Liu, Ye Kang, Ningxin Qu, Chenhui Kong and Ye Han
    Citation: BMC Cancer 2023 23:801
    Content type: Research Published on:

  45. Pemetrexed is an efficacious multi-targeted antifolate with acceptable toxicity for non-squamous non-small cell lung cancer (non-Sq NSCLC) and malignant pleural mesothelioma. Vitamin B12 and folic acid as prem...

    Authors: Yuichiro Takeda, Go Naka, Yuki Katsuya, Konomi Kobayashi, Manabu Suzuki, Masao Hashimoto, Satoshi Hirano and Yukari Uemura
    Citation: BMC Cancer 2023 23:800
    Content type: Research Published on:

  46. In research designs that rely on observational ratings provided by two raters, assessing inter-rater reliability (IRR) is a frequently required task. However, some studies fall short in properly utilizing stat...

    Authors: Ming Li, Qian Gao and Tianfei Yu
    Citation: BMC Cancer 2023 23:799
    Content type: Matters Arising Published on:

    The Research to this article has been published in BMC Cancer 2022 22:1285

  48. The optimal treatment for multiple brain metastases has been recently controversially discussed.This study was aimed to explore the feasibility of Hippocampus-Avoidance Whole-Brain Radiotherapy plus a simultan...

    Authors: Xiaoliang Wang, Jinping Chen, Zhanquan Lei, Haihong Chen, Yufang Zhang, Gang Liu, Shaomin Li, Zhenhua Zheng and Hui Wang
    Citation: BMC Cancer 2023 23:796
    Content type: Research article Published on:

  49. The aim of study was to evaluate survival outcome and limb function in cancer patients with proximal limbs metastasis. Associated factors on survival outcome and limb function were identified. The comparative ...

    Authors: Chao Zhang, Jun Wang, Haixiao Wu, Yile Lin, Vladimir P. Chekhonin, Karl Peltzer, Artem V. Bukharov, Andrey D. Kaprin, Xu Guo and Zheng Liu
    Citation: BMC Cancer 2023 23:795
    Content type: Research Published on:

  50. The association between specific genetic mutations and immunotherapy benefits has been widely known, while such studies in pan-cancer are still limited. SPEN, mainly involved in X chromosome inactivation (XCI)...

    Authors: Ya-Dong Li, Hao Huang, Zheng-Ju Ren, Ye Yuan, Hao Wu and Chuan Liu
    Citation: BMC Cancer 2023 23:793
    Content type: Research Published on:

Featured videos

View featured videos from across the BMC-series journals

Submit manuscript

Follow

BMC Cancer

ISSN: 1471-2407

Contact us